Product name: Segetalin C
Synonym name: Segetalin E ；Vaccarin C
Catalogue No.: BP5097
Cas No.: 177602-12-9
Formula: C₄₃H₅₆N₈O₈
Mol Weight: 812.969
Botanical Source:
Type of Compound: Botanical Cyclopeptides

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.

For Reference Standard and R&D, Not for Human Use Directly.

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Segetalin C is a class of medicinal herbs derived from the traditional Chinese medicinal material Vaccaria segetalis (scientific name: Vaccaria segetalis). ) cyclic peptide natural products. As an important member of the cyclic peptide family, Wang Buliuxing cyclic peptide C has gradually become a hot topic in natural product pharmacology research in recent years due to its unique chemical structure and significant biological activity. Previous studies have shown that Wang Buliuxing Cyclopeptide C demonstrates good pharmacological potential in regulating physiological functions, anti-tumor, and hormone regulation, especially in ovarian removal rat models, significantly increasing uterine weight, suggesting possible estrogen-like activity. In addition, this compound has regulatory effects on various tumor-related targets such as MCL1, BCL2, and STAT3, demonstrating its promising application in the anti-tumor field.

This paper will systematically review the chemical structure and physicochemical properties of Wang Bu Liuxing Cyclic Peptide C, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics. Combined with current research progress, it will explore its clinical application potential and future directions, providing theoretical basis and reference for in-depth research and drug development of this natural product.

Chemical structure and physicochemical properties

Wang Buliuxing Cyclic Peptide C is a cyclic peptide compound with a complex molecular formula and a molecular weight of 812.9690, indicating it is a naturally occurring cyclic peptide with a relatively large molecular weight. Its LogP value is 1.1699, indicating that the compound has moderate lipid solubility and some water solubility (0.7474), which positively affects its bioavailability and in vivo distribution. TPSA (Topological Polar Surface Area) is 222.1400, indicating high polarity, which may affect its ability to pass through cell membranes and the blood-brain barrier permeability, which in this compound exhibits low permeability.

Structurally, Wang Bu Liuxing cyclic peptide C is formed by multiple amino acid residues closed by amide bonds forming a cyclic structure. The cyclic peptide structure imparts high conformational stability and enzymatic hydrolysis stability, thereby affecting its pharmacological activity and metabolism in vivo. These cyclic peptide structures typically form high-affinity binds to protein targets, regulating multiple signaling pathways.

Additionally, Wang Buliuxing Cyclic Peptide C did not exhibit hERG channel inhibitory activity, suggesting a low risk of cardiotoxicity; The Ames test result was 0.0, indicating no significant genotoxicity, providing preliminary support for safety evaluation.

Plant Origins and Extraction Methods

Wang Bu Liu Xing Ring Peptide C mainly originates from the traditional Chinese medicinal herb Wang Bu Liu Xing, a dried mature seed of Vaccaria segetalis, a plant in the Caryophyllaceae family. Wang Bu Liuxing seeds are widely used in traditional Chinese medicine for various clinical indications, including promoting blood circulation to remove blood stasis, promoting urination, and relieving stranguria. Its rich cyclic peptide components form the basis of its main active substances.

Common extraction methods for Wang Buliuxing Circular Peptide C include organic solvent extraction, ultrasound-assisted extraction, and column chromatography separation. The general process is: first, ethanol or methanol is used to extract Wangbuliuxing seeds to extract the crude extract; Subsequently, the crude extract was separated and purified using liquid-liquid partitioning, silica gel column chromatography, or high-performance liquid chromatography (HPLC), ultimately obtaining high-purity Wang Bu Liuxing Cyclic Peptide C.

In recent years, with advances in separation technology, supercritical fluid extraction and membrane separation techniques have also been introduced, improving extraction efficiency and purity, reducing solvent residues, and promoting large-scale preparation of this compound.

Pharmacological activity research

Promotes uterine weight gain

Wang Buliuxing Cyclopeptide C showed a significant uterine weight increase effect in ovarian-removed rat models, at a dose of 2.5 mg/kg. This suggests that it may have estrogen-like activity, mimicking the stimulating effect of estrogen on uterine tissue, promoting endometrial proliferation and improved blood flow. This action has potential value in treating hormone deficiencies, osteoporosis, and related gynecological diseases in postmenopausal women.

Antitumor activity

Wang Buliuxing Cyclopeptide C demonstrated significant antitumor activity across various in vitro and in vivo tumor models. Its targets involve several key tumor-related molecules, including:

• MCL1 and BCL2: Both are anti-apoptotic proteins that regulate the apoptosis pathway. Wang Buliuxing Cycloptic Peptide C promotes tumor cell apoptosis by downregulating these proteins.
• STAT3: As a signal transduction and transcription activator, STAT3 plays an important role in the proliferation and immune evasion of various tumor cells. Wang Buliuxing Cyclopeptide C can inhibit STAT3 activation and block its downstream signaling pathway.
• MMP2: Matrix metalloproteinase 2, involved in tumor cell invasion and metastasis. This compound can inhibit MMP2 activity and limit the migration ability of tumor cells.
• TOP1, TOP2A: Topoisomerase I and IIα, involved in DNA replication and transcription. Wang Buliuxing Cyclopeptide C inhibits its activity and inhibits tumor cell proliferation.
• HIF1A: Hypoxia-inducing factor 1α, regulates tumor cells' adaptation to hypoxic environments. This cyclopeptide can reduce HIF1A expression and inhibit tumor angiogenesis and metabolic reprogramming.
• MAPK1: Mitogen-activated protein kinase, involved in cell proliferation and survival. Wang Buliuxing Cyclic Peptide C inhibits tumor cell growth by regulating the MAPK1 signaling pathway.
• ESR1 and CYP19A1: Etrogen receptor α and aromatase, respectively, involved in the development of hormone-dependent tumors. This compound may exert anti-tumor effects by modulating hormone signaling pathways.

In summary, Wang Buliuxing cyclopeptide C demonstrates broad-spectrum anti-tumor potential by coordinating regulation of tumor cell proliferation, apoptosis, invasion, and metastasis through multiple targets and pathways.

Other pharmacological effects

In addition to the main activities mentioned above, preliminary studies on Wang Buliuxing Cyclopeptide C have also reported on its anti-inflammatory, immunomodulatory, and antioxidant properties, suggesting its potential to play an auxiliary role in the treatment of various diseases and warranting further in-depth exploration.

Mechanism of action and molecular targets

The pharmacological action of Wang Buliuxing Cyclopeptide C depends on its specific binding and regulation of multiple molecular targets. The cyclic peptide structure endows it with strong target affinity and selectivity, effectively intervening in intracellular signaling networks.

• Regulation of anti-apoptotic proteins: By inhibiting the expression of MCL1 and BCL2, Wang Buliuxing Cyclopeptide C lifts the anti-apoptotic barrier of tumor cells and induces programmed cell death.
• Signal transduction inhibition: STAT3 and MAPK1 are key regulatory factors for tumor cell survival and proliferation. Their inhibitory effect blocks the transmission of extracellular signals into the nucleus, suppressing tumor cell proliferation and metastasis.
• Inhibition of matrix-degrading enzymes: By inhibiting MMP2 activity, tumor cells are prevented from degrading the extracellular matrix, limiting its invasion and distant metastasis.
• DNA topoisomerase inhibition: Inhibition of TOP1 and TOP2A leads to DNA replication and transcription disorders, blocking the progression of the tumor cell cycle.
• Intervention in hypoxia adaptation mechanisms: Inhibits HIF1A expression, interferes with tumor cells' adaptation to hypoxic environments, and suppresses tumor angiogenesis.
• Hormone signaling regulation: By modulating ESR1 and CYP19A1, it influences the growth environment of hormone-dependent tumors and exerts anti-tumor effects.

These multi-target mechanisms demonstrate Wang Buliuxing's cyclopeptide C complex and comprehensive bioregulatory functions, laying a solid foundation for its development as an antitumor drug.

Druggability evaluation and pharmacokinetics

From the perspective of druggability, Wang Buliuxing Cyclic Peptide C demonstrated good safety and relatively ideal drug properties. Its moderate LogP value ensures a certain degree of lipid solubility in the body while also considering water solubility, which facilitates drug absorption and distribution. A higher TPSA indicates stronger polarity and low blood-brain barrier permeability, reducing the risk of central nervous system toxicity.

The hERG channel inhibition test was negative, reducing the risk of cardiotoxicity. The Ames test showed no mutagenicity, indicating a low genotoxicity risk. Additionally, the cyclic peptide structure gives it high enzyme stability, which may extend its half-life in vivo and improve bioavailability.

However, cyclic peptide natural products commonly suffer from poor oral absorption and complex metabolism. Wang Buliuxing Cycloptic Peptide C also requires further systematic pharmacokinetic studies, including detailed elucidation of absorption, distribution, metabolism, and excretion (ADME) characteristics. Currently, related research is relatively limited. In the future, in vivo and in vitro models and pharmacometabolomics methods will be used to deeply reveal the behavioral patterns in vivo.

Prospects and outlooks for clinical applications

Based on the outstanding performance of Wang Buliuxing Ring Peptide C in promoting uterine weight gain and multi-target anti-tumor activity, it has broad clinical application prospects in gynecological diseases and tumor treatment.

• Gynecological hormone replacement therapy: Uterinotropic effects in ovarian removal rat models suggest it can serve as a natural estrogen-like drug, used as an adjunct therapy for menopausal syndrome, osteoporosis, and hormone-related diseases, offering natural origins and high safety.
• Antitumor drug development: Multi-target anti-tumor mechanisms give them potential value in the treatment of solid tumors and hematologic malignancies. In the future, combining medicinal chemical modification with nanodelivery technology can optimize its pharmacokinetic properties to enhance efficacy and targeting.
• Combination therapy strategy: Due to its diverse mechanisms of action, Wangbuluxing cyclopeptide C can be used in combination with existing chemotherapy or targeted drugs to enhance antitumor efficacy and reduce resistance risk.

Future research should focus on preclinical safety evaluation, dosage optimization, administration routes, and long-term toxicology studies, while integrating modern drug design technologies to carry out structural modification and derivative development to enhance drug potential.

Conclusion

Wang Bu Liuxing Ring Peptide C, as a natural cyclic peptide with a unique structure and multiple bioactive properties, demonstrates significant application value in gynecological hormone regulation and anti-tumor therapy. Its multi-target and multi-mechanism mode of action offers new ideas for the development of natural anti-tumor drugs. Although research on its pharmacokinetics and clinical applications is still in its early stages, its good safety and significant pharmacological activity lay a solid foundation for further in-depth research.

In the future, by integrating modern medicinal chemistry, molecular biology, and pharmacological technologies, systematic structural optimization, mechanism analysis, and preclinical evaluation of Wang Bu Liuxing Cyclopeptide C will help promote its clinical translation and ultimately achieve its widespread application in disease treatment.